The intent of this study is to see if the rate that the body breaks down l-methamphetamine (l-MA) could be used as an accurate estimate for the rate that the body breaks down d-methamphetamine (d-MA). l-MA is sold over the counter as a nasal decongestant where as d-MA is the commonly abused form of methamphetamine.
Subjects will screen at St. Luke's Hospital in San Francisco to determine their eligibility. Once enrolled the study will take two weeks. During the first week subjects attend daily, hour-long outpatient visits at San Francisco General Hospital. At these visits subjects will receive an oral dose of l-methamphetamine, have their vitals read, answer questionnaires and receive a blood draw. During the second week of the study subjects are admitted to San Francisco General Hospital for a week long inpatient stay. During this stay the subject continues to receive l-methamphetamine but also receives three doses of d-methamphetamine on three separate days. In addition the subject receives blood draws, has their urine collected, and answers questionnaires.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
5mg of l-methamphetamine per day throughout the 2 week study
15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
CPMC Addiction & Pharmacology Research Laboratory (APRL)
San Francisco, California, United States
Serum samples
Time frame: Predose and Multiple Timepoints Post Doses
Urine Samples
Time frame: 24 Hour Inpatient Collection
Questionnaries
Time frame: Predose and Multiple Timepoints Post Doses
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.